• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down1.60% Nasdaq Down0.39%

    Curis, Inc. (CRIS)

    1.32 Up 0.04(3.13%) 4:00PM EST
    ProfileGet Profile for:
    Curis, Inc.
    4 Maguire Road
    Lexington, MA 02421
    United States - Map
    Phone: 617-503-6500
    Fax: 617-503-6501
    Website: http://www.curis.com

    Index Membership:N/A
    Full Time Employees:35

    Business Summary 

    Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase I clinical trials for advanced lymphomas and multiple myeloma; and HER 2-/ ER+ or PR+ breast cancer, and NUT midline carcinoma. It also develops CUDC-427 that is in Phase I clinical trials for advanced solid tumor and lymphomas; programmed death ligand-1 antagonist, which is in preclinical stage for the treatment of cancers; small molecule Interleukin-1 receptor-associated kinase 4 inhibitor that is in preclinical stage for the treatment of hematological cancers; and CUDC-305 drug candidate, which is in trials in patients with systemic mastocytosis and glioblastoma multiforme for the treatment of cancers. In addition, the company offers Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma (BCC). Its Erivedge is also in Phase II clinical trials for preceding excision and/or multiple BCC, and idiopathic pulmonary fibrosis. The company has collaboration agreement with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and collaboration and license agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Curis, Inc.

    Corporate Governance 
    Curis, Inc.’s ISS Governance QuickScore as of Feb 1, 2016 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Ali Fattaey Ph.D., 51
    Chief Exec. Officer, Pres and Director
    Mr. Daniel R. Passeri MSc., J.D., 55
    Vice Chairman and Strategic Advisor
    Mr. Michael P. Gray , 45
    Chief Financial Officer, Principal Accounting Officer, Chief Bus. Officer and Sec.
    Dr. Jaye Viner M.D., MPH, 59
    Chief Medical Officer and Exec. VP
    Mr. Mark W. Noel , 57
    VP of Technology Management & Intellectual Property
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders